Skip to content
Curis Lifesciences logo

Curis Lifesciences

CURIS NSE
₹177.00 No trade today
P/E
7.38
View as Markdown
MCP
Close 4 Nov 2026 ₹177.00 +36.00 +25.5% 1Y
Start ₹141.00

Key Fundamentals

SMEPharmaceuticals & BiotechnologyHealthcare

Price-based figures as of · TTM

ROCE
21.20%
Debt to Equity
0.46
EPS (TTM)
₹24.00
Book Value
₹58.58
Market Cap
—
P/E (TTM)
7.38
P/B
3.02
ROE
21.70%
Dividend Yield
0.00%
EBITDA
₹11.40 Cr
52W High
₹234.75
52W Low
₹83.60
Volume
0

Peer Comparison

Healthcare › Pharmaceuticals

Curis Lifesciences peer comparison
Sun Pharma
₹1,773.4038.81₹4,29,049 Cr4.770.90%16.00%20.50%₹61,631 Cr₹10,987 Cr
Divis Laboratories
₹10,037.5091.10₹2,65,269 Cr15.900.30%16.50%22.00%₹11,230 Cr₹2,925 Cr
Torrent Pharmaceuticals
₹4,738.5078.61₹1,77,061 Cr9.810.82%27.40%15.20%₹17,400 Cr₹2,099 Cr
Zydus Life Science
₹1,188.1026.44₹1,25,446 Cr4.370.08%21.20%21.10%₹28,592 Cr₹4,593 Cr
Laurus Labs
₹2,323.80114.81₹1,25,228 Cr20.720.04%18.30%17.80%₹7,270 Cr₹1,090 Cr
Dr Reddys Laboratories
₹1,374.0035.59₹1,14,543 Cr2.960.58%11.20%13.00%₹33,228 Cr₹3,184 Cr
Cipla
₹1,402.0033.59₹1,12,454 Cr3.200.93%11.60%15.50%₹28,324 Cr₹3,356 Cr
Curis Lifesciences (this company)
₹177.007.38₹146 Cr3.020.00%21.70%21.20%₹9 Cr₹1 Cr
Median 8 companies₹1,587.7037.20₹1,25,337 Cr4.570.44%17.40%19.15%₹22,862 Cr₹3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

43 Weak

Data confidence 98/100

surveillance:ESM1

Category scores

Quality
31
Poor
Returns, margins, earnings quality 22% weight
Valuation
43
Weak
Cheap vs sector & own history 24% weight
Growth
67
Strong
Sales & profit trajectory 9% weight
Financial Health
57
Good
Solvency, leverage, coverage 9% weight
Momentum
95
Strong
Trend strength, vol-adjusted 12% weight
Ownership
41
Weak
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

1
  • Company has a good return on equity (ROE) track record: 3 Years ROE 38.9%

Weaknesses

3
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Company might be capitalizing the interest cost
  • Working capital days have increased from 123 days to 232 days

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallBullish658
OscillatorsNeutral252
Moving AveragesStrong Bullish406

Key readings

RSI (14)
43.48
Neutral
MACD (12,26,9)
−1.46
Bearish
SMA (50)
173.68
Bullish
SMA (200)
126.50
Bullish

As of

Growth Rate

From the financial statements below. 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025.

Revenue

Revenue growth by window
3Y+19.86%
1Y+20.63%

Net profit

Net profit growth by window
3Y+77.86%
1Y+11.43%

Operating cash flow

Operating cash flow growth by window
3YTurned negative
1YOutflow widened by ₹14.39 Cr

Operating margin· change in pp

Operating margin growth by window
3Y+9.10 pp
1Y−3.03 pp

Trailing twelve months: Results are not reported for each of the last eight quarters, so there is no trailing-twelve-month figure.

Revenue by year

Revenue by year, ₹ crore
Mar 2022₹23.70 Cr
Mar 2023₹35.21 Cr
Mar 2024₹35.13 Cr
Mar 2025₹50.26 Cr
Mar 2026₹60.63 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2022₹0.49 Cr
Mar 2023₹1.23 Cr
Mar 2024₹4.87 Cr
Mar 2025₹6.21 Cr
Mar 2026₹6.92 Cr

Half-yearly Results

₹ Cr
CURIS half-yearly results, ₹ crore
Particulars Sep 2024Mar 2025Sep 2025Mar 2026
Sales
15.9
34.36
27.91
32.72
Expenses
12.09
27.43
21.92
27.58
Operating Profit
3.81
6.93
5.99
5.14
OPM %
23.96%
20.17%
21.46%
15.71%
Other Income
−0.02
0.05
0
0.27
Interest
0.5
0.61
0.43
0.71
Depreciation
0.34
0.34
0.34
0.35
PBT
2.95
6.03
5.22
4.35
Tax %
25.42%
33.67%
19.35%
37.7%
Net Profit
2.2
4
4.21
2.71
EPS (₹)
4
6.74
7.09
3.35

Profit & Loss

₹ Cr
CURIS profit and loss, annual, ₹ crore
Particulars Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales
23.7
35.21
35.13
50.26
60.63
Expenses
20.12
31.95
26.74
39.51
49.5
Operating Profit
3.58
3.26
8.39
10.75
11.13
OPM %
15.11%
9.26%
23.88%
21.39%
18.36%
Other Income
0.02
0.34
0.31
0.02
0.27
Interest
1.62
1.33
0.85
1.11
1.14
Depreciation
0.75
0.73
0.68
0.67
0.7
PBT
1.23
1.54
7.17
8.99
9.56
Tax %
59.35%
20.13%
32.22%
30.92%
27.62%
Net Profit
0.49
1.23
4.87
6.21
6.92
EPS (₹)
0.89
2.24
8.85
10.46
8.56
Div. Payout %
0%
0%
0%
0%
0%

Balance Sheet

₹ Cr
CURIS balance sheet, annual, ₹ crore
Particulars Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
0.5
0.5
0.5
5.93
8.08
Reserves
−1.4
−0.18
5.37
10.58
39.27
Borrowings
17.62
16.19
17.09
15.61
21.59
Other Liabilities
10.68
13.16
10.91
10.48
12.58
Total Liabilities
27.4
29.67
33.87
42.6
81.52
Fixed Assets
12.33
12.2
11.59
10.99
10.78
CWIP
0
0
0
0.02
1.33
Investments
0.01
0.01
0.01
0.01
0.01
Other Assets
15.06
17.46
22.27
31.58
69.4
Total Assets
27.4
29.67
33.87
42.6
81.52

Cash Flow

₹ Cr
CURIS cash flow, annual, ₹ crore
Particulars Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
4.95
3.35
0.28
−2.03
−16.42
Investing
−0.37
−0.55
−0.06
−0.02
−1.59
Financing
−4.58
−2.76
0.05
1.94
20.87
Net Cash Flow
−0.01
0.04
0.27
−0.11
2.86
Free Cash Flow
4.56
2.77
0.21
−2.06
−18.24
CFO/EBITDA
138
103
3
−5
−127

Ratios

CURIS financial ratios, annual
Particulars Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
96.1
98.17
105
55.05
67.55
Inventory Days
208
115
273
347
694
Days Payable
360
263
210
113
166
Cash Conversion Cycle
−55.01
−49.58
168
289
595
Working Capital Days
−16.02
−20.84
36.26
99.27
232
ROCE %
—
17.21%
40.64%
36.64%
21.2%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Curis Lifesciences insights

60 extracted metrics across FY22–FY26.

Shareholding Pattern

As of Sep 2026

  • Promoters 68.03%
  • Public 15.78%
  • Others 10.51%
  • DIIs 4.63%
  • FIIs 1.05%

No promoter shares pledged as of 14 Oct 2026

Change vs previous quarter

Documents

Frequently Asked Questions about Curis Lifesciences

What does Curis Lifesciences Ltd do?
Incorporated in 2010, Curis Lifesciences Limited is a pharmaceutical company that specializes in developing, manufacturing, and distributing a diverse range of products.
Where is Curis Lifesciences Ltd (CURIS) listed?
Curis Lifesciences Ltd trades as CURIS on the NSE.
Which sector does Curis Lifesciences Ltd belong to?
Curis Lifesciences Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the PE ratio of Curis Lifesciences Ltd?
Curis Lifesciences Ltd trades at a PE ratio of 7.38 as of 4 Nov 2026, on earnings per share of ₹24, against a book value of ₹58.58 per share.
What is the 52-week high and low of Curis Lifesciences Ltd?
Over the last 52 weeks Curis Lifesciences Ltd has traded between ₹83.6 and ₹234.75 as of 4 Nov 2026.
What is the Return on Equity (ROE) of Curis Lifesciences Ltd?
Curis Lifesciences Ltd reported a return on equity of 21.70%. Its debt-to-equity ratio is 0.46.

Company Information

Incorporated in 2010, Curis Lifesciences Limited is a pharmaceutical company that specializes in developing, manufacturing, and distributing a diverse range of products.

Website curisls.com
Listed 14 Nov 2025
Face Value ₹10

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/CURIS.md for Curis Lifesciences Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month